Logo image
Management of Aortic Stenosis in Patients With End-Stage Renal Disease on Hemodialysis
Journal article   Open access   Peer reviewed

Management of Aortic Stenosis in Patients With End-Stage Renal Disease on Hemodialysis

Amgad Mentias, Milind Y. Desai, Marwan Saad, Phillip A. Horwitz, James D. Rossen, Sidakpal Panaich, Hani Jneid, Samir Kapadia and Mary Vaughan-Sarrazin
Circulation. Cardiovascular interventions, Vol.13(8), pp.e009252-e009252
08/01/2020
DOI: 10.1161/CIRCINTERVENTIONS.120.009252
PMCID: PMC7422925
PMID: 32772570
url
https://doi.org/10.1161/CIRCINTERVENTIONS.120.009252View
Published (Version of record) Open Access

Abstract

Background: Patients with end-stage renal disease on hemodialysis (ESRD-HD) and aortic stenosis have poor prognosis. The role of transcatheter aortic valve replacement (TAVR) in this high-risk population is debated. Methods: We compared the outcomes among ESRD-HD Medicare beneficiaries who were managed with TAVR, surgical AVR (SAVR), or conservative management for aortic stenosis between 2015 and 2017, using overlap propensity score weighting analysis to control for differences in treatment assignment. The primary outcome was all-cause mortality and was compared between treatment groups as well as to age-sex matched mortality for ESRD-HD in the US population. Secondary outcomes included trend of heart failure hospitalizations. Results: A total of 8107 ESRD-HD patients with aortic stenosis were included, 4130 (50%) underwent TAVR, 2565 (31.6%) underwent SAVR, and 1412 (17.4%) were managed conservatively. TAVR patients had more comorbidities and higher frailty compared with the other 2 groups. Thirty-day mortality was lower with TAVR compared with SAVR (4.6% versus 12.8%,P<0.01). After a median follow-up of 465 days (interquartile range, 261-759), on overlap propensity score weighting analysis, there was no difference in mortality between TAVR and SAVR (adjusted hazard ratio, 1.02 [95% CI, 0.91-1.15],P=0.7), and mortality was lower with TAVR compared with conservative management (adjusted hazard ratio, 0.53 [95% CI, 0.47-0.60],P<0.001). Standardized mortality ratios with TAVR, SAVR, and conservative management compared with age-sex matched ESRD-HD US population were 1.24, 1.27, and 1.83, respectively. The rate of heart failure admissions declined after TAVR (incidence rate ratio, 0.55 [95% CI, 0.48-0.62],P<0.001) and SAVR (incidence rate ratio, 0.76 [95% CI, 0.65-0.88],P<0.001). Conclusions: In ESRD-HD patients with aortic stenosis, mortality was lower in the short-term with TAVR compared with SAVR but comparable in the mid-term. AVR is associated with an improvement in survival and reduction in heart failure hospitalizations compared with conservative management.
Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Life Sciences & Biomedicine Science & Technology

Details

Logo image